Abstract
Pseudomyxoma peritonei (PMP) is the intraperitoneal accumulation of mucus due to a mucinous tumor. PMP predominantly occurs in low-grade carcinomas. The incidence rate of PMP is one to two cases per million people per year. The standard therapy of PMP comprises complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. PMP recurs in about 50% of patients, and 30–40% are unable to receive the standard treatment because of its invasiveness. Therefore, novel therapies are of the utmost necessity. For basic and pre-clinical research, patient-derived cell lines are essential resources. However, only two PMP cell lines have been reported. Thus, we established a novel PMP cell line from resected metastatic PMP tissue. The cell line, named NCC-PMP1-C1, was maintained for more than 5 months and was passaged 25 times. NCC-PMP1-C1 cells demonstrated multiple deletions, slow growth, tumorigenic ability, and dissemination of tumor cells in nude mice. We also used NCC-PMP1-C1 cells to screen drugs, which demonstrated a significant response to daunorubicin HCl, homoharringtonine, mitomycin C, and ponatinib. The NCC-PMP1-C1 cell line is the first PMP cell line derived from metastasized tissue and will be a potential resource for basic and pre-clinical research of metastasized PMP.
Highlights
Pseudomyxoma peritonei (PMP) is the intraperitoneal accumulation of mucus derived from mucinous tumors [1]
PMP is divided into two groups: disseminated peritoneal adenomucinosis tumors (DPAMs), showing low-grade cytologic atypia and minimal architectural complexity, and peritoneal mucinous adenocarcinomas tumors (PMCAs), demonstrating high-grade cytologic atypia and/or complex epithelial proliferation
We established a cell line derived from a patient with metastatic pseudomyxoma peritonei (PMP)
Summary
Pseudomyxoma peritonei (PMP) is the intraperitoneal accumulation of mucus derived from mucinous tumors [1]. PMP is a rare disease, with an incidence of one to two cases per million per year [8]. PMP shows various clinical manifestations due to the dissemination of mucin-producing tumor cells in the peritoneal 4.0/). PMP is divided into two groups: disseminated peritoneal adenomucinosis tumors (DPAMs), showing low-grade cytologic atypia and minimal architectural complexity, and peritoneal mucinous adenocarcinomas tumors (PMCAs), demonstrating high-grade cytologic atypia and/or complex epithelial proliferation. Distant metastasis is extremely rare in PMP [11,12], 50% of patients develop recurrence [13], 30–40% of patients are unable to receive the hybrid treatment because of its invasiveness [14], and patients with recurrent disease are difficult to cure [14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
